Table 1 Characteristics of included trials that compare fluconazole vs mould-active antifungal prophylaxis

From: Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials

Study author	Pub year	Multi-centre	N	Population	Mould-active dose	Fluconazole dose	Prophylaxis end	Surrogate testing ^a
Bodey et al, 1994	1994	No	77	Hem malignancy	CAB 0.17 mg kg⁻¹ per dose IV TID	400 mg per dose PO/IV OD	ANC>1000 μl⁻¹ or 8 weeks	No
Annaloro et al, 1995	1995	No	59	HSCT (auto, allo)	Itraconazole 400 mg per dose PO OD	300 mg per dose PO OD	Neutropenia resolution	No
Huijgens et al, 1999a	1999	No	202	Hem malignancy, HSCT (auto)	Itraconazole 100 mg per dose PO BID	50 mg per dose PO BID	ANC>500 μl⁻¹	No
Morgenstern et al, 1999b	1999	Yes	581	Hem malignancy, HSCT (auto, allo)	Itraconazole 2.5 mg kg⁻¹ per dose PO BID	100 mg per dose PO OD	ANC>1000 μl⁻¹ × 7 days	No
Timmers et al, 2000a	2000	No	24	Hem malignancy, HSCT (auto, allo)	Amphotericin B colloidal dispersion 2 mg kg⁻¹ per dose IV OD	200 mg per dose PO OD	ANC>500 μl⁻¹	No
Wolff et al, 2000a	2000	Yes	355	HSCT (auto, allo)	CAB 0.2 mg kg⁻¹ per dose IV OD	400 mg per dose PO/IV OD	ANC>500 μl⁻¹	No
Koh et al, 2002b	2002	No	186	HSCT (auto, allo)	CAB 0.2 mg kg⁻¹ per dose IV OD	200 mg per dose PO OD	ANC>500 μl⁻¹ × 3 days	No
Winston et al, 2003	2003	Yes	138	HSCT (allo)	Itraconazole 200 mg per dose IV BID × 4 then 200 mg per dose IV OD × 12 then 200 mg per dose PO BID until D+100	400 mg per dose IV OD × 14 then 400 mg per dose PO OD until D+100	D+100	No
Marr et al, 2004	2004	No	299	HSCT (allo)	Itraconazole 2.5 mg kg⁻¹ per dose PO TID or 200 mg per dose IV OD	400 mg per dose PO/IV OD	D+120–180 days	No
van Burik et al, 2004	2004	Yes	882	HSCT (auto, allo)	Micafungin 50 mg per dose IV OD	400 mg per dose IV OD	ANC⩾500 μl⁻¹ × 5 days or D+42	No
Choi et al, 2005	2005	No	78	HSCT (allo)	Itraconazole 200 mg per dose PO OD	200 mg per dose PO OD	NS	No
Glasmacher et al, 2006	2006	Yes	494	Hem malignancy	Itraconazole 5 mg kg⁻¹ per dose PO BID	400 mg per dose PO/IV OD	ANC>1000 μl⁻¹ or 8 weeks	No
Oren et al, 2006a	2006	No	195	Hem malignancy, HSCT (auto, allo)	Itraconazole 200 mg per dose PO/IV BID	400 mg per dose PO/IV OD	Neutropenia resolution or 8 weeks	No
Cornely et al, 2007	2007	Yes	544	Hem malignancy	Posaconazole 200 mg per dose PO/IV BID	400 mg per dose PO/IV OD	Neutropenia resolution or 12 weeks	No
Ito et al, 2007a	2007	Yes	209	Hem malignancy	Itraconazole 200 mg per dose PO OD	200 mg per dose PO OD	ANC >1000 μl⁻¹ or leukocytes⩾2 μl⁻¹	Yes
Ullmann et al, 2007	2007	Yes	600	GVHD	Posaconazole 200 mg per dose PO TID	400 mg per dose PO OD	112 days	Yes
Hiramatsu et al, 2008a	2008	No	100	HSCT (auto, allo)	Micafungin 150 mg per dose IV OD	400 mg per dose IV OD	ANC>500 μl⁻¹ × 5 or D+42	No
Sawada et al, 2009b	2009	Yes	107	Hem malignancy, HSCT (allo/auto)	Micafungin 2 mg kd⁻¹ per dose IV OD	10 mg kg⁻¹ per dose IV OD	ANC>500 μl⁻¹	No
Ota et al, 2010	2010	No	73	HSCT (auto, allo)	Itraconazole 200 mg per dose PO/IV OD	400 mg per dose PO/IV OD	D+28	No
Wingard et al, 2010	2010	Yes	600	HSCT (allo)	Voriconazole 200 mg per dose PO BID	400 mg per dose PO OD	D+100	Yes

Abbreviations: allo=allogeneic; ANC=absolute neutrophil count; auto=autologous; BID=twice daily; CAB=conventional amphotericin B; D=day of HSCT; GVHD=graft-vs-host disease; Hem=haematological; HSCT=haematopoietic stem cell transplantation; IV=intravenous; N=total number of subjects randomised; NS=not specified; OD=once daily; Pub=publication; PO=oral; TID=three times daily.
^a Surrogate marker evaluation for invasive fungal infection includes galactomannin and beta-D glucan testing.

Back to article page

Table 1 Characteristics of included trials that compare fluconazole vs mould-active antifungal prophylaxis

Search

Quick links